Business Context and Reporting Period
Company: Aquestive Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 7, 2024
Purpose: Regulation FD Disclosure to furnish an investor presentation regarding Q1 2024 earnings supplemental materials to institutional investors and analysts.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely as a vehicle to disclose the existence and availability of an investor presentation (Exhibit 99.1) containing such data.
Material Changes
No material financial changes or comparative period data are detailed within the text of this Form 8-K. The document references an attached presentation for detailed financial updates.
Guidance, Outlook, and Risks
- Management Commentary: The company is providing an investor presentation to discuss Q1 2024 results.
- Forward-Looking Statements: The filing explicitly states that the information in the investor presentation may be amended or updated at any time.
- Legal Disclaimer: The information furnished in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Q1 Earnings Supplemental Materials) for actual financial figures and operational metrics.
- Verify the availability of the investor presentation on the company website (www.aquestive.com), noting the company reserves the right to discontinue access.
- Confirm that any forward-looking statements in the presentation are understood as subject to change and not legally filed under Section 18 of the Exchange Act.